Paula Abello-Cáceres, Javier Pizarro-Bauerle, Carlos Rosas, Ismael Maldonado, Lorena Aguilar-Guzmán, Carlos González, Galia Ramírez, Jorge Ferreira, Arturo Ferreira
BACKGROUND: For several decades now an antagonism between Trypanosoma cruzi infection and tumor development has been detected. The molecular basis of this phenomenon remained basically unknown until our proposal that T. cruzi Calreticulin (TcCRT), an endoplasmic reticulum-resident chaperone, translocated-externalized by the parasite, may mediate at least an important part of this effect. Thus, recombinant TcCRT (rTcCRT) has important in vivo antiangiogenic and antitumor activities. However, the relevant question whether the in vivo antitumor effect of T...
September 13, 2016: BMC Cancer